Thieler Law Corp advises investors with losses exceeding $100,000 of the June 29, 2015 lead plaintiff deadline in a class action lawsuit filed against Aerie Pharmaceuticals Inc (NASDAQ: AERI) (“Aerie Pharmaceuticals” or “the Company”). The suit is pending in the U.S. District Court for the District of New Jersey and investors, who purchased Aerie Pharmaceuticals securities between August 6, 2014 and April 23, 2015, have until June 29, 2015 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Aerie Pharmaceuticals securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 866-6157 or emailing mail@thielerlaw.com.  No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period, Aerie Pharmaceuticals made false and misleading statements and/or allegedly failed to disclose adverse information regarding the Company’s plans for Rhopressa, including that Rhopressa was not performing as well as timolol and would not lead to commercial success for Aerie Pharmaceuticals. As a result of these false and misleading statements and/or omissions, NASDAQ: AERI securities traded at an artificially high stock price of $35.39 per share during the Class Period.

Then on April 23, 2015, Aerie Pharmaceuticals issued a press release announcing the results of its first Phase 3 registration trial for Rhopressa. Stated in the release, “[t]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily RhopressaTM compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma.”

Following the release of this news, Aerie Pharmaceuticals Inc stock declined $22.52 per share to close at $12.87 per share on April 24, 2015, a drop of close to 64%.

If you were negatively impacted by your investment in Aerie Pharmaceuticals securities between August 6, 2014 and April 23, 2015 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185